TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 54.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,775 shares of the biopharmaceutical company's stock after purchasing an additional 8,338 shares during the period. Allspring Global Investments Holdings LLC's holdings in TG Therapeutics were worth $898,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock worth $469,454,000 after purchasing an additional 209,190 shares during the last quarter. Soleus Capital Management L.P. lifted its position in shares of TG Therapeutics by 5.8% during the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock worth $80,705,000 after purchasing an additional 146,702 shares during the last quarter. Clearbridge Investments LLC purchased a new stake in TG Therapeutics in the fourth quarter valued at $55,237,000. Northern Trust Corp lifted its position in TG Therapeutics by 8.6% in the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock valued at $46,141,000 after acquiring an additional 120,785 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in TG Therapeutics by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after acquiring an additional 84,904 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

TGTX traded down $0.59 on Friday, reaching $37.08. The company had a trading volume of 957,478 shares, compared to its average volume of 2,876,739. TG Therapeutics, Inc. has a 1 year low of $16.65 and a 1 year high of $46.48. The stock has a market capitalization of $5.89 billion, a PE ratio of 154.50 and a beta of 1.91. The company has a quick ratio of 3.04, a current ratio of 4.02 and a debt-to-equity ratio of 1.03. The stock has a 50-day moving average price of $36.05 and a 200-day moving average price of $35.30.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. TG Therapeutics's revenue was up 90.4% on a year-over-year basis. During the same period last year, the firm earned ($0.07) earnings per share. As a group, research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 price target for the company in a research report on Thursday. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

Insider Buying and Selling

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the transaction, the director directly owned 228,816 shares in the company, valued at approximately $8,452,463.04. The trade was a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 10.64% of the company's stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.